AMEX · Biotechnology

Impact BioMedical, Inc. (IBO) Stock

$4.39 +6.81% AMEX: IBO Healthcare

Valuation

MetricValue
Price$4.39
Market Cap$37.51M
P/E Ratio-4.48
P/B Ratio4.38
P/S Ratio1347.46
EPS (TTM)$-0.38
52-Week High$10.51
52-Week Low$4.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE13.70%
ROA4.71%
ROCE-34.67%
Gross Margin-17.44%
Operating Margin-117.82%
Net Margin-329.69%
Debt/Equity0.00
Current Ratio0.22

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-3.0M$-3.0M$-4.0M$-29.0M$-4.0M
Net Profit$-7.0M$-7.0M$-4.0M$-25.0M$-12.0M
EPS$-7.70$-7.70$-0.88$-0.09$-4.80
Op Margin-6808.0%-6808.0%——-13343.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$56.0M$46.0M$45.0M$20.0M$17.0M
Total Liabilities$17.0M$14.0M$16.0M$13.0M$2.0M
Cash$0$0$0$2.0M$0
Borrowings$13.0M$10.0M$12.0M$9.0M$0

Latest News

Impact BioMedical to Effect 1-for-12.62 Reverse Stock Split MT Newswires · Sep 11, 2026 Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.) GlobeNewswire · Sep 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-2.0M$-3.0M$-6.0M$-2.0M
Investing Cash Flow$-1.0M$-1.0M$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$0$0$0$3.0M$-2.0M
Free Cash Flow$-3.0M$-3.0M$-3.0M$-6.0M$-2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-117.58
FCF Yield-1.08%
Quick Ratio0.13
Interest Coverage-19.45
Return 1Y-31.34%
Return 3Y—
Return 5Y—

Ownership

Insiders Held89.02%
Institutions Held3.45%
Institutions Float Held31.44%
Institutional HolderSharesReport Date
Geode Capital Management, LLC1,192,9252026-03-31
Vanguard Capital Management LLC708,1682026-03-31
State Street Corporation607,8972026-03-31
Vanguard Fiduciary Trust Co585,1982026-03-31
Blackrock Inc.259,9462026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADILAdial Pharmaceuticals, Inc $4.04 +1.76% -0.26 $10.61M 0.00%
AIMAIM ImmunoTech Inc. $0.18 -1.75% -0.05 $7.04M 0.00%
BCLIBrainstorm Cell Therapeutics Inc. $0.98 +6.52% -1.04 $10.81M 0.00%
CYCN $23.52 +0.00% -2.42 $15.73M 0.00%
MLECMoolec Science SA $2.60 -37.95% -0.02 $1.89M 0.00%

About Impact BioMedical, Inc.

Impact BioMedical, Inc. is led by CEO Frank D. Heuszel, publicly traded since 2024.

Impact BioMedical, Inc. (IBO) stock trades at $4.39 with a market capitalization of $37.51M. The stock is valued at a price-to-earnings (P/E) ratio of -4.48, price-to-book of 4.38, price-to-sales of 1347.46. Over the past 52 weeks the stock has ranged between $4.10 and $10.51, and currently trades 58.2% below its 52-week high.

On profitability, Impact BioMedical, Inc. generates a return on equity (ROE) of 13.70%, above the typical market average, return on capital employed of -34.67%, an operating margin of -117.82%, a net profit margin of -329.69%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1174.49 +0.42% JNJ Johnson & Johnson $261.01 +1.76% ABBV AbbVie Inc. $277.37 +1.82% MRK Merck & Company, Inc. Common Stock (new) $145.82 +2.42% UNH UnitedHealth Group Incorporated Common Stock (DE) $378.36 +2.00% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $658.89 +1.06% AMGN Amgen Inc. $415.88 +2.07% GILD Gilead Sciences, Inc. $151.29 +2.85% ABT Abbott Laboratories $99.18 +0.70% NVO Novo Nordisk A/S $38.39 +0.54%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides